Drugs / ANF-Rho
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT02533362 | Oct 2015 → Oct 2016 | — | Prolong Pharmaceuticals | Withdrawn | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT03559387 | Aug 2017 → Apr 2018 | neutropenia | Prolong Pharmaceuticals | Terminated | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ANF-Rho | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02533362 ↗ |
| Modality | Protein / enzyme biologic | “Pegylated version of recombinant human granulocyte-colony stimulating factor (G-CSF)” NCT02533362 ↗ |
| Route | Subcutaneous | “ANF-RHO™ will be administered to the subjects as a subcutaneous injection” NCT03559387 ↗ |